This report provides a thorough look at Germany’s regulatory regime in relation to CBD and cannabis, not only providing a detailed overview of the numerous laws governing the subject, but also offering detailed examples within each section and offering comprehensive analysis of each. In addition to discussion surrounding finished products and extracts, the report also offers analysis regarding Germany’s stance on medical and recreational cannabis.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyThis will report will enable you to obtain a detailed understanding of Germany’s complex regulatory regime, along with a full list of all of the relevant laws and governing bodies associated with the subject. Not only will you gain information about each aspect, including finished products, extracts and import and export laws, but you will also be provided with the most up-to-date information relating to Germany’s stance on medical and recreational cannabis.
Table of contents1 Executive summary
2 Hemp plant
3 Extracts
4 Finished products
5 Medicinal cannabis
6 Recreational cannabis
7 Import and export requirements
8 Relevant laws
9 Relevant bodies
MethodologyThe research is completely original and conducted by CBD-Intel’s multilingual legal analysis team using several sources, including online and offline resources and data, specialised legal software, interviews with key stakeholders and government officials, and via the collaboration with local lawyers and on-the-ground profession.
Latest reportsThis report provides a thorough look at Germany’s regulatory regime in relation to CBD and cannabis, not only providing a detailed overview of the numerous laws governing the subject, but also offering detailed examples within each section and offering comprehensive analysis of each. In addition to discussion surrounding finished products and extracts, the report also offers analysis regarding Germany’s stance on medical and recreational cannabis.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.